

04-29-04

PTO/SB/21 (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**+** 

		Application Number	10/686,322	
TDANIONITTAL			Filing Date	October 14, 2003
	TRANSMITTAL	-	First Named Inventor	CHU, GILBERT
	FORM		Group Art Unit	1634
	(to be used for all correspondence after in	itial filing)	Examiner Name	
	Total Number of Pages in This Submissi	ion 4+REFS.	Attorney Docket Number	STAN-277
		ENCLOSUR	ES (check all that apply)	
	Fee Transmittal Form	1	nment Papers Application)	After Allowance Communication to Group
		Drawin	ng(s)	Appeal Communication to Board
	After Final  Affidavits/declaration(s)  Extension of Time Request  Express Abandonment Request  Information Disclosure Statement  Certified Copy of Priority  Documents  Petition  Provision  Provision  Prower of  Change  Address  Termina		ing-related Papers	of Appeals and Interferences  Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<u> </u>			n	
			n to Convert to a	Proprietary Information
			ional Application of Attorney, Revocation	Status Letter
$\boxtimes$			e of Correspondence	Other Enclosure(s) (please
			nal Disclaimer	identify below):
			st for Refund	Form PTO/SB/08A     Coples of cited references     Postcard
	Incomplete Application	CD, No	umber of CD(s	
	Response to Missing Parts under 37 CFR 1.52 or 1.53	Remarks		
	SIGNA	TURE OF APPL	ICANT, ATTORNEY, OR	AGENT
Signing A (Reg. No. Signature		& FRANCIS LLP		
Date	April 27, 2004	rword		
	F	XPRESS MAII	LABEL NO. EV3339976	27

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



## Express Mail No. EV333997627

## INFORMATION DISCLOSURE STATEMENT

Address to: Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Attorney Docket	STAN-277
First Named Inventor	CHU, GILBERT
Application Number	10/686,322
Confirmation No.	7388
Filing Date	October 14, 2003
Group Art Unit	1634
Examiner Name	

Title:

"METHODS AND COMPOSITIONS FOR DETERMINING RISK OF TREATMENT

TOXICITY"

Sir:

This is an Information Disclosure Statement submitted for the Examiner's consideration. A Form PTO-SB/08A listing the references and copies of the cited references accompany this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record.

This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one of the above references constitutes prior art to the present application within the meaning of 35 U.S.C.§102.

As applicants have not yet received a first Action on the merits, no fee is believed to be required for filing this Disclosure Statement. If, however, the PTO finds that for some reason a fee is due, our Deposit Account No. 50-0815, Order No. STAN-277 may be charged thereon.

Respectfully submitted, BOZICEVIC, FIELD & FRANCIS LLP

Date:

April 27 2004

BOZICEVIC, FIELD & FRANCIS LLP 200 Middlefield Road, Suite 200

Menlo Park, CA 94025

Telephone: (650) 327-3400 Facsimile: (650) 327-3231

By:

Pamela J. Sherwood

Registration No. 36,677

PTO/SB/08a (05-03)

A A	PR 2 7 2004 Under Paperw	ork Reduction	Act of 1995, n		ent and Trademark Office; U.S. DEPARTMENT OF COMMERCE tion of information unless it contains a valid OMB control number.	
Substitut	CRRECINGUE STAIPTO			Complete if Known		
•				Application Number	10/686,322	
	INFORMATION DIS	CLOSUF	RE	Filing Date	October 14, 2003	
	STATEMENT BY A	PPLICAN	ΙT	First Named Inventor	CHU, GILBERT	
				Art Unit	1634	
	(use as many sheets as	necessary)		Examiner Name		
Sheet	1_	of	2	Attorney Docket Number	STAN-277	
				<del></del>		

U.S. PATENT DOCUMENTS									
Examiner	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages or Relevant				
Initials'	No.1	Number-Kind Code <sup>4</sup> (if known)	MM-DD-YYYY	Applicant of Cited Document	Figures Appear				
		US-							

		FOREIG	N PATENT DO	CUMENTS			
Examiner Initials'	Cite No.1	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Τ¢	
		WO 01/84139	11-08-2001	TUSHER et al.			
		OTHER PRIOR ART—NO	ON PATENT LI	TERATURE DOCUMENT	S		
Examiner Initials*	Cite No. <sup>1</sup>	item (book, magazine, journal, se	rial, symposium, cata	, title of the article (when appropriation, etc.), date, page(s), volume		T <sup>2</sup>	
·		Barber et al., RELATINSHIP BETWEEN IN VITRO CHROMOSOMAL READIOSENSITIVITY OF PERIPHERAL BLOOD LYMPHOCYTES AND THE EXPRESSION OF NORMAL TISSUE DAMAGE FOLLOWING RADIOTHERAPY FOR BREAST CANCER, (2000), Radiother Oncol, 55:179-86  Brock et al., IN VITRO RADIOSENSITIVITY AND NORMAL TISSUE DAMAGE, (2000),					
		Brock et al., IN VITRO RADIOSE Radiother Oncol, 55:93-94	NSITIVITY AN	D NORMAL TISSUE DA	MAGE, (2000),		
	Crompton et al., ALTERED APOPTOTIC PROFILES IN IRRADIATED PATIENTS WITH INCREASED TOXICITY, (1999), Int J Radiat Oncol Biol Phys, 45:707-714						
Johansen et al., RELATIONSHIP BETWEEN THE IN VITRO RADIOSENSITIVITY OF SKIN FIBROBLASTS AND THE EXPRESSION OF SUBCUTANEOUS FIBROSIS, TELANGIECTASIA, AND SKIN ERYTHEMA AFTER RADIOTHERAPY, (1996), Radiother Oncol, 40:101-9							
age.	Peacock et al., CELLULAR RADIOSENSITIVITY AND COMPLICATION RISK AFTER CURATIVE RADIOTHERAPY, (2000), Radiother Oncol, 55:173-8						
garan e		Russell et al., LOW PREDICTIVE FOR FIBROSIS DEVELOPMENT F (1998), Int J Radiat Biol, 73:661	OLLOWING RA	TRINSIC FIBROBLAST F ADIOTHERAPY FOR BR	RADIOSENSITIVITY EAST CANCER,		

Examiner	 Date	
Signature	Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitu	ute for form 1449B/PTO	<u> </u>		Complete if Known		
, m				Application Number	10/686,322	
-	INFORMATION DISCLOSURE			Filing Date	October 14, 2003	
	STATEMENT BY AF	PPLICA	ANT	First Named Inventor	CHU, GILBERT	
	•			Group Art Unit	1634	
	(use as many sheets as	necessar	v)	Examiner Name		
Sheet	·- · 2	of	2	Attorney Docket Number	STAN-277	

		OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),	T²
		Tibshirani et al., DIAGNOSIS OF MULTIPLE CANCER TYPES BY SHRUNKEN CENTROIDS OF GENE EXPRESSION, (2002) Proc. Natl. Acad. Sci. 99:6567-6572	
***		Tusher et al., SIGNIFICANCE ANALYSIS OF MICROARRAYS APPLIED TO THE IONIZING RADIATION RESPONSE, (2001), Proc. Natl. Acad. Sci., 98:5116-5121	
100			
ا سمعی			
	1		
-	-		
	* · · · · · · · · · · · · · · · · · · ·		

Examiner Date Considered		 		
Signature	Examiner		Date	
Olghadie	Signature		Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.